As per NAVADHI Market Research, the global pharmaceutical industry [3] will we worth USD 1.57 trillion by 2023.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory.
AstraZeneca reported revenue of USD 22.090 billion for the FY 2018 which saw an increase of 1.67% compared to FY 2017. This revenue is expected to increase by 6% and reach USD 23.415 billion by FY 2019. AstraZeneca revenue decreased at a CAGR of 2.99% during FY 2013 to FY 2018.
AstraZeneca registered the highest revenue from Cardiovascular, Renal, and Metabolism therapy area at USD 6.710 billion which accounted for 31.88% of its total sales in FY 2018. In FY 2018, AstraZeneca registered the highest revenue from the United States market at USD 7.24 billion which accounted for 32.78% of its total sales in FY 2018. This was followed by China with revenue of USD 3.778 billion accounting for 17.10% of total FY 2018 sales and United Kingdom with revenue of USD 2.39 billion and accounting for 10.82% of total FY 2018 sales.
• This report provides detailed information about AstraZeneca PLC including value chain analysis, financial performance, business strategy, and SWOT analysis.
• The report identifies the growth drivers and inhibitors for the global pharmaceutical market.
• This report provides information about current and future trends for the global pharmaceutical market.
*If Applicable.